Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,956 questions in 143 reviews · Musculoskeletal
current versionsNo studies 555 · 28.4%Ungraded 107 · 5.5%Very low 255 · 13%Low 555 · 28.4%Moderate 357 · 18.3%High 127 · 6.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Methotrexate vs placebo Outcomes(time frame of absolute effects) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Treatment responsea · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Sustained clinically inactive diseaseb(12 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 1.37 [0.91, 2.06] | 1 study · 207 participants | Low |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Function · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Pain · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Participant global assessment of well‐being · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Serious adverse events(12 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | Very low |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Withdrawals due to adverse events(12 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 8.75 [0.48, 160.4] | 1 study · 207 participants | Low |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Outcomes(time frame of absolute effects) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Treatment responsea(4 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 1.4 [0.93, 2.1] | 1 study · 94 participants | Low |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Sustained clinically inactive diseasec · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs placebo Treatment responsea(up to 6 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 1.67 [1.21, 2.31] | 3 studies · 328 participants | Low |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Function · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | 1 study · 94 participants | Low |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Pain · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Participant global assessment of well‐being · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | 1 study · 94 participants | Low |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Serious adverse events(4 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 0.14 [0.01, 2.69] | 1 study · 94 participants | Low |
Methotrexate vs alternative disease‐modifying antirheumatic drugs Withdrawals due to adverse events(4 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 0.33 [0.04, 3.09] | 1 study · 94 participants | Low |
Methotrexate vs placebo Sustained clinically inactive diseasec · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs placebo Function · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate vs placebo Pain Mean improvement in pain on motion from baseline, 0–100 scale, 0 represents no pain(up to 6 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | 1 study · 114 participants | Low |
Methotrexate vs placebo Participant global assessment of well‐being(up to 6 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 1.23 [0.88, 1.72] | 1 study · 176 participants | Low |
Methotrexate vs placebo Serious adverse events(up to 6 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 0.63 [0.04, 8.97] | 3 studies · 328 participants | Low |
Methotrexate vs placebo Withdrawals due to adverse events (up to 6 months) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | RR 3.46 [0.6, 19.79] | 3 studies · 328 participants | Low |
Oral methotrexate plus intra‐articular glucocorticoid vs intra‐articular glucocorticoid alone Outcomes(time frame of absolute effects) · children and young people with JIA Methotrexate for juvenile idiopathic arthritis (2024) · Cochrane | no estimate extracted | NR | No studies |
Intermittent/cyclic etidronate 400 mg/day vs placebo Clinical vertebral fractures · postmenopausal women with a lower risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane | RR 3.03 [0.32, 28.44] | NR | Low |
Intermittent/cyclic etidronate 400 mg/day vs placebo Wrist fractures · postmenopausal women with a higher risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane | RR 0.9 [0.13, 6.04] | NR | Very low |
Intermittent/cyclic etidronate 400 mg/day vs placebo Withdrawals due to adverse events · postmenopausal women with a higher risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane | RR 1.09 [0.54, 2.18] | NR | Very low |
Intermittent/cyclic etidronate 400 mg/day vs placebo Serious adverse events · postmenopausal women with a higher risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane | no estimate extracted | NR | Very low |
Intermittent/cyclic etidronate 400 mg/day vs placebo Non‐vertebral fractures · postmenopausal women with a lower risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane | RR 0.56 [0.2, 1.61] | NR | Moderate |
Intermittent/cyclic etidronate 400 mg/day vs placebo Hip fractures · postmenopausal women with a lower risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane | no estimate extracted | NR | Very low |
Intermittent/cyclic etidronate 400 mg/day vs placebo Wrist fractures № of participants: 0 (0 RCTs) · postmenopausal women with a lower risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane | no estimate extracted | NR | No studies |
Intermittent/cyclic etidronate 400 mg/day vs placebo Withdrawals due to adverse events · postmenopausal women with a lower risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane | RR 1.41 [0.81, 2.47] | NR | Low |
Intermittent/cyclic etidronate 400 mg/day vs placebo Serious adverse events · postmenopausal women with a lower risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane | RR 0.9 [0.52, 1.54] | NR | Moderate |
Intermittent/cyclic etidronate 400 mg/day vs placebo Clinical vertebral fractures № of participants: 0 (0 RCTs) · postmenopausal women with a higher risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane | no estimate extracted | NR | No studies |
Intermittent/cyclic etidronate 400 mg/day vs placebo Non‐vertebral fractures · postmenopausal women with a higher risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane | RR 1.07 [0.72, 1.58] | NR | Low |
Intermittent/cyclic etidronate 400 mg/day vs placebo Hip fractures · postmenopausal women with a higher risk for fracturesa Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women (2024) · Cochrane | RR 0.93 [0.17, 5.19] | NR | Very low |
Manual therapy, prescribed exercises or both vs placebo PainScale: numerical rating scale (0 to 10, 0 is no pain) · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | 1 study · 23 participants | Low |
Manual therapy, prescribed exercises or both vs minimal or no intervention Health‐related quality of lifefScale: SF‐36 (0 to 100, 100 indicates perfect health) · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | 2 studies · 113 participants | Low |
Manual therapy, prescribed exercises or both vs minimal or no intervention Participant‐reported treatment success · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | RR 1.36 [0.96, 1.93] | 6 studies · 770 participants | Low |
Manual therapy, prescribed exercises or both vs minimal or no intervention Proportion of overall withdrawals · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | RR 0.86 [0.66, 1.12] | 12 studies · 1147 participants | Very low |
Manual therapy, prescribed exercises or both vs minimal or no intervention Proportion with any adverse event · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | RR 3.69 [0.98, 13.97] | 6 studies · 457 participants | Very low |
Manual therapy, prescribed exercises or both vs minimal or no intervention Proportion with a serious adverse event · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | NR | No studies |
Manual therapy, prescribed exercises or both vs placebo DisabilityScale: 0 to 100 (0 is no disability) · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | 1 study · 23 participants | Low |
Manual therapy, prescribed exercises or both vs placebo Quality of life · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | NR | No studies |
Manual therapy, prescribed exercises or both vs placebo Participant‐reported treatment success · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | NR | No studies |
Manual therapy, prescribed exercises or both vs placebo Proportion of withdrawals · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | NR | No studies |
Manual therapy, prescribed exercises or both vs placebo Proportion with adverse events · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | NR | No studies |
Manual therapy, prescribed exercises or both vs placebo Proportion with a serious adverse event · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | NR | No studies |
Manual therapy, prescribed exercises or both vs minimal or no intervention PainScale: VAS (0 to 10, 0 is no pain) · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | 12 studies · 1023 participants | Low |
Manual therapy, prescribed exercises or both vs minimal or no intervention DisabilityScale: Disability questionnaires (0 to 100, 0 is no disability) · lateral elbow pain Manual therapy and exercise for lateral elbow pain (2024) · Cochrane | no estimate extracted | 10 studies · 732 participants | Low |